Abstract
Budipine was introduced into clinical trials in 1976 and reports have since pointed its efficacy upon parkinsonian symptoms, especially tremor. It is effective in long-term treatment without loss of efficacy and its tolerance is remarkable. The exact neuro-pharmacologic mode of action of budipine in Parkinson’s disease is not yet fully understood. An Oxotremorine antagonism as well as antagonistic effects on reserpine- and haloperidole-induced catalepsy have been shown in animal experiments suggesting a dopaminergic mode (Brand and Menge 1982; see the chapter by Menge and Brand) of action. On the other hand, weak anticholinergic properties have been demonstrated also (see the chapter by Menge and Brand).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Menge HG, Brand U (1982) Pharmacological summary of Budipine, a new 4,4-diphenylpiperidine derivative used in treating Parkinson’s disease. Arzneimittelforsch 32: 85–98
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Ketz, E. (1985). Open Clinical Trial of Budipine in 25 Tremor-Dominant Parkinsonian Patients. In: Gerstenbrand, F., Poewe, W., Stern, G. (eds) Clinical Experiences with Budipine in Parkinson Therapy. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-95455-9_19
Download citation
DOI: https://doi.org/10.1007/978-3-642-95455-9_19
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-13764-1
Online ISBN: 978-3-642-95455-9
eBook Packages: Springer Book Archive